Simone Sanna-Cherchi

Simone Sanna-Cherchi

Auto-generated profile, based on publicly available information

Simone Sanna-Cherchi

Division of Nephrology, Department of Medicine, Columbia University, New York, New York

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
JXJingyuan Xie
Jingyuan Xie
LLLili Liu
Lili Liu
NMNikol Mladkova
Nikol Mladkova
YLYifu Li
Yifu Li
HRHong Ren
Hong Ren
KKKrzysztof Kiryluk
Krzysztof Kiryluk
Membranous Nephropathy (MN) is a rare autoimmune cause of kidney failure. Here we report a genome-wide association study (GWAS) for primary MN in 3,782 cases and 9,038 controls of East Asian and European ancestries. We discover two previously unreported loci, NFKB1 (rs230540, OR = 1.25, P = 3.4 × 10−12) and IRF4 (rs9405192, OR = 1.29, P = 1.4 × 10−14), fine-map the PLA2R1 locus (rs17831251, OR = 2.25, P = 4.7 × 10−103) and report ancestry-specific effects of three classical HLA alleles: DRB1*1501 in East Asians (OR = 3.81, P = 2.0 × 10−49), DQA1*0501 in Europeans (OR = 2.88, P = 5.7 × 10−93), and DRB1*0301 in both ethnicities (OR = 3.50, P = 9.2 × 10−23 and OR = 3.39, P = 5.2 × 10−82, respectively). GWAS loci explain 32% of disease risk in East Asians and 25% in Europeans, and correctly re-classify 20–37% of the cases in validation cohorts that are antibody-negative by the serum anti-PLA2R ELISA diagnostic test. Our findings highlight an unusual genetic architecture of MN, with four loci and their interactions accounting for nearly one-third of the disease risk.

19 June 2023 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
KKKrzysztof Kiryluk
Krzysztof Kiryluk
ESElena Sanchez-Rodriguez
Elena Sanchez-Rodriguez
XZXu-Jie Zhou
Xu-Jie Zhou
FZFrancesca Zanoni
Francesca Zanoni
LLLili Liu
Lili Liu
AGAli G. Gharavi
Ali G. Gharavi

21 December 2018 in Nature Genetics
Verified
Journal Article
Open access
PDF file
MVMiguel Verbitsky
Miguel Verbitsky
RWRik Westland
Rik Westland
APAlejandra Perez
Alejandra Perez
KKKrzysztof Kiryluk
Krzysztof Kiryluk
QLQingxue Liu
Qingxue Liu
SSSimone Sanna-Cherchi
Simone Sanna-Cherchi
Congenital anomalies of the kidney and urinary tract (CAKUT) are a major cause of pediatric kidney failure. We performed a genome-wide analysis of copy number variants (CNVs) in 2,824 cases and 21,498 controls. Affected individuals carried a significant burden of rare exonic (that is, affecting coding regions) CNVs and were enriched for known genomic disorders (GD). Kidney anomaly (KA) cases were most enriched for exonic CNVs, encompassing GD-CNVs and novel deletions; obstructive uropathy (OU) had a lower CNV burden and an intermediate prevalence of GD-CNVs; and vesicoureteral reflux (VUR) had the fewest GD-CNVs but was enriched for novel exonic CNVs, particularly duplications. Six loci (1q21, 4p16.1-p16.3, 16p11.2, 16p13.11, 17q12 and 22q11.2) accounted for 65% of patients with GD-CNVs. Deletions at 17q12, 4p16.1-p16.3 and 22q11.2 were specific for KA; the 16p11.2 locus showed extensive pleiotropy. Using a multidisciplinary approach, we identified TBX6 as a driver for the CAKUT subphenotypes in the 16p11.2 microdeletion syndrome.

4 April 2017 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
WBWhitney Besse
Whitney Besse
KDKe Dong
Ke Dong
JCJungmin Choi
Jungmin Choi
SPSohan Punia
Sohan Punia
SFSorin V. Fedeles
Sorin V. Fedeles
SSStefan Somlo
Stefan Somlo
Dominantly inherited isolated polycystic liver disease (PCLD) consists of liver cysts that are radiologically and pathologically identical to those seen in autosomal dominant polycystic kidney disease, but without clinically relevant kidney cysts. The causative genes are known for fewer than 40% of PCLD index cases. Here, we have used whole exome sequencing in a discovery cohort of 102 unrelated patients who were excluded for mutations in the 2 most common PCLD genes, PRKCSH and SEC63, to identify heterozygous loss-of-function mutations in 3 additional genes, ALG8, GANAB, and SEC61B. Similarly to PRKCSH and SEC63, these genes encode proteins that are integral to the protein biogenesis pathway in the endoplasmic reticulum. We inactivated these candidate genes in cell line models to show that loss of function of each results in defective maturation and trafficking of polycystin-1, the central determinant of cyst pathogenesis. Despite acting in a common pathway, each PCLD gene product demonstrated distinct effects on polycystin-1 biogenesis. We also found enrichment on a genome-wide basis of heterozygous mutations in the autosomal recessive polycystic kidney disease gene PKHD1, indicating that adult PKHD1 carriers can present with clinical PCLD. These findings define genetic and biochemical modulators of polycystin-1 function and provide a more complete definition of the spectrum of dominant human polycystic diseases.

2 January 2018 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
SSSimone Sanna-Cherchi
Simone Sanna-Cherchi
RWRik Westland
Rik Westland
Gian Marco GhiggeriGian Marco Ghiggeri
Gian Marco Ghiggeri
AGAli G. Gharavi
Ali G. Gharavi
The clinical spectrum of congenital anomalies of the kidney and urinary tract (CAKUT) encompasses a common birth defect in humans that has significant impact on long-term patient survival. Overall, data indicate that approximately 20% of patients may have a genetic disorder that is usually not detected based on standard clinical evaluation, implicating many different mutational mechanisms and pathogenic pathways. In particular, 10% to 15% of CAKUT patients harbor an unsuspected genomic disorder that increases risk of neurocognitive impairment and whose early recognition can impact clinical care. The emergence of high-throughput genomic technologies is expected to provide insight into the common and rare genetic determinants of diseases and offer opportunities for early diagnosis with genetic testing.

23 February 2017 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
ELEsther Lopez-Rivera
Esther Lopez-Rivera
YLYangfan P. Liu
Yangfan P. Liu
MVMiguel Verbitsky
Miguel Verbitsky
BABlair R. Anderson
Blair R. Anderson
VCValentina P. Capone
Valentina P. Capone
SSSimone Sanna-Cherchi
Simone Sanna-Cherchi
The DiGeorge syndrome, the most common of the microdeletion syndromes, affects multiple organs, including the heart, the nervous system, and the kidney. It is caused by deletions on chromosome 22q11.2; the genetic driver of the kidney defects is unknown. We conducted a genomewide search for structural variants in two cohorts: 2080 patients with congenital kidney and urinary tract anomalies and 22,094 controls. We performed exome and targeted resequencing in samples obtained from 586 additional patients with congenital kidney anomalies. We also carried out functional studies using zebrafish and mice. We identified heterozygous deletions of 22q11.2 in 1.1% of the patients with congenital kidney anomalies and in 0.01% of population controls (odds ratio, 81.5; P=4.5×10−14). We localized the main drivers of renal disease in the DiGeorge syndrome to a 370-kb region containing nine genes. In zebrafish embryos, an induced loss of function in snap29, aifm3, and crkl resulted in renal defects; the loss of crkl alone was sufficient to induce defects. Five of 586 patients with congenital urinary anomalies had newly identified, heterozygous protein-altering variants, including a premature termination codon, in CRKL. The inactivation of Crkl in the mouse model induced developmental defects similar to those observed in patients with congenital urinary anomalies. We identified a recurrent 370-kb deletion at the 22q11.2 locus as a driver of kidney defects in the DiGeorge syndrome and in sporadic congenital kidney and urinary tract anomalies. Of the nine genes at this locus, SNAP29, AIFM3, and CRKL appear to be critical to the phenotype, with haploinsufficiency of CRKL emerging as the main genetic driver. (Funded by the National Institutes of Health and others.)